Progressive Dopamine Neuron Loss in Parkinson's Disease: The Multiple Hit Hypothesis

Animal models have been an essential tool for researchers and clinicians in their efforts to study and treat Parkinson's disease (PD). Thus, the various ways 6-hydroxydopamine is employed, the use of MPTP in rodents and nonhuman primates, the prenatal exposure to bacterial endotoxin, the postnatal exposure to environmental toxins such as paraquat and rotenone, the assessment of dopamine (DA) neurons in genetic knockout mouse, and even the behavioral analysis of fruit flies and worms have added significantly to our knowledge base of PD—or have they? Are these animal models manifesting a true model of PD? Have the 7786 published studies (to date) on PD with animal models led to a clearer understanding of its etiology, treatment, or progression? In this review we critically assess this question. We begin with a succinct history of the major contributions, which have led to the current animal models of PD. We then evaluate the primary issue of the progressive loss of DA neurons, which, except for a few studies, has not been addressed in animal models of PD, even though this is the major pathological characteristic of the disease. Lastly, we discuss the possibility that more than one risk factor for PD may be necessary to develop an animal model that shows synergy—the progressive loss of DA neurons. Thus, the multiple hit hypothesis of PD—that is, the effect of more then one risk factor—may be the start of new era in animal models of PD that is one step closer to mimicking the pathology of PD in humans.

[1]  A. Albanese,et al.  Chronic administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine to monkeys: Behavioural, morphological and biochemical correlates , 1993, Neuroscience.

[2]  L. Iversen Inhibition of catecholamine uptake by 6-hydroxydopamine in rat brain. , 1970, European journal of pharmacology.

[3]  W. Bender,et al.  A Drosophila model of Parkinson's disease , 2000, Nature.

[4]  R. Krüger,et al.  The role of alpha-synuclein gene multiplications in early-onset Parkinson's disease and dementia with Lewy bodies. , 2005, Journal of neural transmission.

[5]  E. Bézard,et al.  A chronic MPTP model reproducing the slow evolution of Parkinson's disease: evolution of motor symptoms in the monkey , 1997, Brain Research.

[6]  P. Bertolucci,et al.  Chronic exposure to the fungicide maneb may produce symptoms and signs of CNS manganese intoxication , 1988, Neurology.

[7]  Todd B. Sherer,et al.  Chronic systemic pesticide exposure reproduces features of Parkinson's disease , 2000, Nature Neuroscience.

[8]  A. Carlsson,et al.  3,4-Dihydroxyphenylalanine and 5-Hydroxytryptophan as Reserpine Antagonists , 1957, Nature.

[9]  J. Langston MPTP neurotoxicity: an overview and characterization of phases of toxicity. , 1985, Life sciences.

[10]  C. Marsden,et al.  Further treatment with MPTP does not produce parkinsonism in marmosets showing behavioural recovery from motor deficits induced by an earlier exposure to the toxin , 1989, Neuropharmacology.

[11]  W. Nicklas,et al.  Inhibition of NADH-linked oxidation in brain mitochondria by 1-methyl-4-phenyl-pyridine, a metabolite of the neurotoxin, 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine. , 1985, Life sciences.

[12]  E. Richfield,et al.  Developmental pesticide exposures and the Parkinson's disease phenotype. , 2005, Birth defects research. Part A, Clinical and molecular teratology.

[13]  T. Dawson,et al.  Role of neuronal nitric oxide in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced dopaminergic neurotoxicity. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[14]  N. Uretsky,et al.  EFFECTS OF 6‐HYDROXYDOPAMINE ON CATECHOLAMINE CONTAINING NEURONES IN THE RAT BRAIN , 1970, Journal of neurochemistry.

[15]  O. Isacson,et al.  Parkinson's disease: interpretations of transplantation study are erroneous , 2001, Nature Neuroscience.

[16]  F. Hefti,et al.  Potential environmental neurotoxins related to 1-methyl-4-phenylpyridinium: Selective toxicity of 1-methyl-4-(4′-acetamidophenyl)-pyridinium and 1-methyl-4-cyclohexylpyridinium for dopaminergic neurons in culture , 1990, Experimental Neurology.

[17]  S. Udenfriend,et al.  2,4,5-TRIHYDROXYPHENETHYLAMINE, A NEW METABOLITE OF 3,4-DIHYDROXYPHENETHYLAMINE , 1959 .

[18]  David Blum,et al.  Molecular pathways involved in the neurotoxicity of 6-OHDA, dopamine and MPTP: contribution to the apoptotic theory in Parkinson's disease , 2001, Progress in Neurobiology.

[19]  D. Perl,et al.  Systemic exposure to proteasome inhibitors causes a progressive model of Parkinson's disease , 2004, Annals of neurology.

[20]  S. Udenfriend,et al.  Chemical, Enzymatic and Metabolic Studies on the Mechanism of Oxidation of Dopamine1 , 1959 .

[21]  G. Corsini,et al.  Norepinephrine loss exacerbates methamphetamine-induced striatal dopamine depletion in mice. , 1995, European journal of pharmacology.

[22]  S. W. Ranson,et al.  CATALEPSY CAUSED BY LESIONS BETWEEN THE MAMMILLARY BODIES AND THIRD NERVE IN THE CAT , 1932 .

[23]  O. Hornykiewicz,et al.  [The L-3,4-dioxyphenylalanine (DOPA)-effect in Parkinson-akinesia]. , 1961, Wiener klinische Wochenschrift.

[24]  A. Graybiel,et al.  The substantia nigra of the human brain. II. Patterns of loss of dopamine-containing neurons in Parkinson's disease. , 1999, Brain : a journal of neurology.

[25]  J. Delay,et al.  Neuroleptic effects of chlorpromazine in therapeutics of neuropsychiatry. , 1955, International record of medicine and general practice clinics.

[26]  S. Totterdell,et al.  Mouse model of Parkinsonism: a comparison between subacute MPTP and chronic MPTP/probenecid treatment , 2001, Neuroscience.

[27]  N Vanacore,et al.  Parkinsonism after chronic exposure to the fungicide maneb (manganese ethylene-bis-dithiocarbamate). , 1994, Scandinavian journal of work, environment & health.

[28]  C. Olanow,et al.  Fetal nigral transplantation as a therapy for Parkinson's disease , 1996, Trends in Neurosciences.

[29]  Robert L. Nussbaum,et al.  Mutation in the α-Synuclein Gene Identified in Families with Parkinson's Disease , 1997 .

[30]  E. Richfield,et al.  Developmental Pesticide Models of the Parkinson Disease Phenotype , 2005, Environmental health perspectives.

[31]  E. Richfield,et al.  A Fetal Risk Factor for Parkinson’s Disease , 2004, Developmental Neuroscience.

[32]  P. Carvey,et al.  In utero bacterial endotoxin exposure causes loss of tyrosine hydroxylase neurons in the postnatal rat midbrain , 2002, Movement disorders : official journal of the Movement Disorder Society.

[33]  E. Richfield,et al.  Developmental exposure to the pesticides paraquat and maneb and the Parkinson's disease phenotype. , 2002, Neurotoxicology.

[34]  F. Fazio,et al.  Striatal dopaminergic denervation in early and late onset Parkinson's disease assessed by PET and the tracer [11C]FECIT: preliminary findings in one patient with autosomal recessive parkinsonism (Park2) , 2002, Neurological Sciences.

[35]  P. Carvey,et al.  Prenatal exposure to the bacteriotoxin lipopolysaccharide leads to long-term losses of dopamine neurons in offspring: a potential, new model of Parkinson's disease. , 2003, Frontiers in bioscience : a journal and virtual library.

[36]  Montagu Ka Catechol Compounds in Rat Tissues and in Brains of Different Animals , 1957 .

[37]  F. Cicchetti,et al.  Cell implantation therapies for Parkinson's disease using neural stem, transgenic or xenogeneic donor cells. , 2001, Parkinsonism & related disorders.

[38]  J. Perlmutter,et al.  Prevalence of parkin gene mutations and variations in idiopathic Parkinson's disease. , 2005, Parkinsonism & related disorders.

[39]  D. Calne,et al.  AETIOLOGY OF PARKINSON'S DISEASE , 1983, The Lancet.

[40]  J. Poirier,et al.  Comparative behavioral, biochemical and pigmentary effects of MPTP, MPP+ and paraquat in Rana pipiens. , 1985, Life sciences.

[41]  R. Blakely,et al.  C. elegans: a novel pharmacogenetic model to study Parkinson's disease. , 2001, Parkinsonism & related disorders.

[42]  J. Kordower,et al.  Striatal trophic factor activity in aging monkeys with unilateral MPTP-induced parkinsonism , 2005, Experimental Neurology.

[43]  U. Ungerstedt,et al.  6-Hydroxy-dopamine induced degeneration of central monoamine neurons. , 1968, European journal of pharmacology.

[44]  R. F. Shore,et al.  Diorthosubstituted Polychlorinated Biphenyls in Caudate Nucleus in Parkinson's Disease , 1998, Experimental Neurology.

[45]  F. Hefti,et al.  Toxic effects of potential environmental neurotoxins related to 1-methyl-4-phenylpyridinium on cultured rat dopaminergic neurons. , 1989, The Journal of pharmacology and experimental therapeutics.

[46]  P. Holtz,et al.  Fermentativer Abbau von l-Dioxyphenylalanin (Dopa) durch Niere , 1938, Naunyn-Schmiedebergs Archiv für experimentelle Pathologie und Pharmakologie.

[47]  E. Richfield,et al.  Age‐related irreversible progressive nigrostriatal dopaminergic neurotoxicity in the paraquat and maneb model of the Parkinson's disease phenotype , 2003, The European journal of neuroscience.

[48]  M. Vila,et al.  The 1‐Methyl‐4‐Phenyl‐1,2,3,6‐Tetrahydropyridine Mouse Model , 2003 .

[49]  A. Lees,et al.  Ageing and Parkinson's disease: substantia nigra regional selectivity. , 1991, Brain : a journal of neurology.

[50]  S. Leurgans,et al.  Rotenone potentiates dopamine neuron loss in animals exposed to lipopolysaccharide prenatally , 2004, Experimental Neurology.

[51]  F. Colpaert,et al.  Effects of locus coeruleus lesions on parkinsonian signs, striatal dopamine and substantia nigra cell loss after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in monkeys: A possible role for the locus coeruleus in the progression of Parkinson's disease , 1991, Neuroscience.

[52]  J S Rakshi,et al.  Measuring the rate of progression and estimating the preclinical period of Parkinson’s disease with [18F]dopa PET , 1998, Journal of neurology, neurosurgery, and psychiatry.

[53]  D B Calne,et al.  Compensatory mechanisms in degenerative neurologic diseases. Insights from parkinsonism. , 1991, Archives of neurology.

[54]  P. Sanberg,et al.  Neural Stem Cells for Cellular Therapy in Humans , 2003 .

[55]  W. Longstreth,et al.  Pesticides and risk of Parkinson disease: a population-based case-control study. , 2005, Archives of neurology.

[56]  R. Krüger,et al.  The role of α-synuclein gene multiplications in early-onset Parkinson’s disease and dementia with Lewy bodies , 2005, Journal of Neural Transmission.

[57]  A. Björklund,et al.  Parkinson-Like Neurodegeneration Induced by Targeted Overexpression of α-Synuclein in the Nigrostriatal System , 2002, The Journal of Neuroscience.

[58]  C. A. Stone,et al.  Effect of 6-hydroxydopamine and some other compounds on the concentration of norepinephrine in the hearts of mice. , 1963, The Journal of pharmacology and experimental therapeutics.

[59]  Bruce G. Jenkins,et al.  Combined PET/MRS brain studies show dynamic and long-term physiological changes in a primate model of Parkinson disease , 1998, Nature Medicine.

[60]  Scott T. Grafton,et al.  Survival of implanted fetal dopamine cells and neurologic improvement 12 to 46 months after transplantation for Parkinson's disease. , 1992, The New England journal of medicine.

[61]  J. Jeng,et al.  Environmental risk factors and Parkinson's disease , 1997, Neurology.

[62]  D. R. Curtis,et al.  Amino acid transmitters in the mammalian central nervous system. , 1974, Ergebnisse der Physiologie, biologischen Chemie und experimentellen Pharmakologie.

[63]  O. Hornykiewicz,et al.  Distribution of noradrenaline and dopamine (3-hydroxytyramine) in the human brain and their behavior in diseases of the extrapyramidal system. , 1960, Parkinsonism & related disorders.

[64]  R. Ramsay,et al.  The reaction sites of rotenone and ubiquinone with mitochondrial NADH dehydrogenase. , 1994, Biochimica et biophysica acta.

[65]  T. Meitinger,et al.  Multiple regions of α‐synuclein are associated with Parkinson's disease , 2005, Annals of neurology.

[66]  M R Franklin,et al.  Toxic effects. , 1977, Science.

[67]  W. Poewe,et al.  Striatal dopamine transporter function in dementia with Lewy bodies and Parkinson's disease , 2001, European Journal of Nuclear Medicine.

[68]  J. Langston,et al.  Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. , 1983, Science.

[69]  L. Iversen Neuronal uptake processes for amines and amino acids. , 1970, Advances in biochemical psychopharmacology.

[70]  P. Carvey,et al.  Combined toxicity of prenatal bacterial endotoxin exposure and postnatal 6-hydroxydopamine in the adult rat midbrain , 2004, Neuroscience.

[71]  E. Richfield,et al.  Potentiated and preferential effects of combined paraquat and maneb on nigrostriatal dopamine systems: environmental risk factors for Parkinson’s disease? , 2000, Brain Research.

[72]  Charcot foot. , 2001, Orthopedic nursing.

[73]  L. Olson,et al.  Neurochemical and Histochemical Characterization of Neurotoxic Effects of 1‐Methyl‐4‐Phenyl‐1,2,3,6‐Tetrahydropyridine on Brain Catecholamine Neurones in the Mouse , 1985, Journal of neurochemistry.

[74]  H. Chapel,et al.  CLINICAL RELEVANCE OF SPECIFIC IgG ANTIBODIES TO CARDIOLIPIN , 1989, The Lancet.

[75]  Janel O. Johnson,et al.  Defining the ends of Parkin exon 4 deletions in two different families with Parkinson's disease , 2005, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.

[76]  George C. Cotzias,et al.  Modification of Parkinsonism--chronic treatment with L-dopa. , 1969, The New England journal of medicine.

[77]  M. Naoi,et al.  Cytotoxicity of dopamine-derived 6,7-dihydroxy-1,2,3,4-tetrahydroisoquinolines. , 1993, Advances in neurology.

[78]  B. Wolozin,et al.  Pathological proteins in Parkinson’s disease , 2007, Journal of Molecular Neuroscience.

[79]  Vellareddy Anantharam,et al.  Dieldrin-induced neurotoxicity: relevance to Parkinson's disease pathogenesis. , 2005, Neurotoxicology.

[80]  J. Sanchez-Ramos,et al.  Toxicity of Dieldrin for Dopaminergic Neurons in Mesencephalic Cultures , 1998, Experimental Neurology.

[81]  Y. C. Chang,et al.  Effects of paraquat on the substantia nigra of the wistar rats: neurochemical, histological, and behavioral studies. , 1996, Toxicology and applied pharmacology.

[82]  G. Nisticó,et al.  Paraquat: a useful tool for the in vivo study of mechanisms of neuronal cell death. , 1998, Pharmacology & toxicology.

[83]  C. Marsden,et al.  Sequential bilateral transplantation in Parkinson's disease: effects of the second graft. , 1999, Brain : a journal of neurology.

[84]  E Bertrand,et al.  Qualitative and quantitative analysis of locus coeruleus neurons in Parkinson's disease. , 1997, Folia neuropathologica.

[85]  E. Bézard,et al.  Kinetics of nigral degeneration in a chronic model of MPTP-treated mice , 1997, Neuroscience Letters.

[86]  Eric K. Richfield,et al.  Risk factors for dopaminergic neuron loss in human α‐synuclein transgenic mice , 2004 .

[87]  J. Langston,et al.  Fate of nigrostriatal neurons in young mature mice given 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: A neurochemical and morphological reassessment , 1986, Brain Research.

[88]  N. Kline,et al.  Use of Rauwolfia serpentina Benth. in neuropsychiatric conditions. , 1954, Annals of the New York Academy of Sciences.